Integra LifeSciences will release its 2025 financial results on February 26, 2026, with a conference call to follow.
Quiver AI Summary
Integra LifeSciences Holdings Corporation announced that it will release its fourth quarter and full year 2025 financial results on February 26, 2026, before the market opens. The management team will hold a conference call at 8:30 a.m. ET, which will be available for live streaming on the company's investor website. Participants are encouraged to register for dial-in details ahead of time. A replay of the call will also be posted on the website after the event. Integra LifeSciences, a leader in medical technology, focuses on enhancing patient care through innovative products and solutions in neurosurgery and tissue reconstruction. For more information, interested parties can visit the company’s website or contact their investor and media relations representatives.
Potential Positives
- Integra LifeSciences is set to release its fourth quarter and full year 2025 financial results, indicating transparency and commitment to stakeholder communication.
- The scheduled conference call showcases the company’s proactive approach to engaging with investors and analysts regarding its financial performance.
- The focus on advanced innovation in neurosurgery and tissue reconstruction positions Integra as a leader in specialized medical technology, emphasizing its commitment to improving patient outcomes.
Potential Negatives
- None
FAQ
When will Integra LifeSciences release its financial results?
Integra LifeSciences will release its fourth quarter and full year 2025 financial results on February 26, 2026.
What time is the Integra LifeSciences conference call?
The conference call will take place at 8:30 a.m. ET on February 26, 2026.
How can I access the Integra LifeSciences earnings call?
You can access the earnings call via live webcast on the Investors section of Integra's website.
Is registration required to participate in the call?
Registration is recommended to receive dial-in details and an individual pin, but not required.
Where can I find additional information about Integra LifeSciences?
For more information, please visit Integra LifeSciences' official website at www.integralife.com.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$IART Insider Trading Activity
$IART insiders have traded $IART stock on the open market 1 times in the past 6 months. Of those trades, 1 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $IART stock by insiders over the last 6 months:
- JEFFREY A GRAVES purchased 9,000 shares for an estimated $102,150
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$IART Revenue
$IART had revenues of $402.1M in Q3 2025. This is an increase of 5.57% from the same period in the prior year.
You can track IART financials on Quiver Quantitative's IART stock page.
$IART Hedge Fund Activity
We have seen 87 institutional investors add shares of $IART stock to their portfolio, and 121 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- KENT LAKE PR LLC added 752,086 shares (+inf%) to their portfolio in Q3 2025, for an estimated $10,777,392
- NEUBERGER BERMAN GROUP LLC added 676,618 shares (+78.8%) to their portfolio in Q3 2025, for an estimated $9,695,935
- MILLENNIUM MANAGEMENT LLC removed 611,848 shares (-73.1%) from their portfolio in Q3 2025, for an estimated $8,767,781
- J. GOLDMAN & CO LP added 598,498 shares (+169.9%) to their portfolio in Q3 2025, for an estimated $8,576,476
- SG AMERICAS SECURITIES, LLC added 380,229 shares (+inf%) to their portfolio in Q4 2025, for an estimated $4,722,444
- RUBRIC CAPITAL MANAGEMENT LP added 300,000 shares (+4.1%) to their portfolio in Q3 2025, for an estimated $4,299,000
- JANE STREET GROUP, LLC removed 298,275 shares (-93.8%) from their portfolio in Q3 2025, for an estimated $4,274,280
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$IART Analyst Ratings
Wall Street analysts have issued reports on $IART in the last several months. We have seen 0 firms issue buy ratings on the stock, and 2 firms issue sell ratings.
Here are some recent analyst ratings:
- Citigroup issued a "Sell" rating on 10/31/2025
- JP Morgan issued a "Underweight" rating on 10/31/2025
To track analyst ratings and price targets for $IART, check out Quiver Quantitative's $IART forecast page.
$IART Price Targets
Multiple analysts have issued price targets for $IART recently. We have seen 4 analysts offer price targets for $IART in the last 6 months, with a median target of $13.0.
Here are some recent targets:
- Ravi Misra from Truist Securities set a target price of $13.0 on 11/03/2025
- Joanne Wuensch from Citigroup set a target price of $11.0 on 10/31/2025
- Robbie Marcus from JP Morgan set a target price of $13.0 on 10/31/2025
Full Release
PRINCETON, N.J., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release fourth quarter and full year 2025 financial results on Thursday, February 26, 2026, prior to the market open. In conjunction with the earnings release, Integra’s management team will host a conference call at 8:30 a.m. ET.
A live webcast will be available on the Investors section of the Company’s website at investor.integralife.com . For those planning to participate on the call, register here to receive dial-in details and an individual pin. While not required, joining 10 minutes before the event starts is recommended. A webcast replay of the conference call will be available on the Investors section of the Company’s website following the call.
About Integra LifeSciences
Integra LifeSciences (Nasdaq: IART) is a global medical technology leader dedicated to restoring lives. We are advancing transformational care through impactful innovation in neurosurgery and tissue reconstruction, specialized fields that demand exceptional expertise and precision. Our portfolio of highly differentiated, gold-standard products and solutions is trusted by healthcare professionals to improve patient outcomes. For the latest news and information about Integra and its products, please visit www.integralife.com.
Investor Relations:
Chris Ward
(609) 772-7736
[email protected]
Media Contact:
Laurene Isip
(609) 208-8121
[email protected]
Integra LifeSciences Holdings Corporation
